Lowest-Rated StocksLowest-RatedNASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis → How a $0.25 cent option contract makes my top traders feel (From DTI) (Ad) Free PTCT Stock Alerts $25.49 +0.28 (+1.11%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$24.00▼$25.6550-Day Range$24.69▼$31.9552-Week Range$17.53▼$59.84Volume1.02 million shsAverage Volume961,586 shsMarket Capitalization$1.95 billionP/E RatioN/ADividend YieldN/APrice Target$33.53 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get PTC Therapeutics alerts: Email Address PTC Therapeutics MarketRank™ Stock AnalysisAnalyst RatingReduce1.85 Rating ScoreUpside/Downside31.6% Upside$33.53 Price TargetShort InterestBearish13.31% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.81Based on 16 Articles This WeekInsider TradingSelling Shares$165,506 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.94) to ($5.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.32 out of 5 starsMedical Sector275th out of 907 stocksPharmaceutical Preparations Industry116th out of 422 stocks 2.9 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.85, and is based on 3 buy ratings, 5 hold ratings, and 5 sell ratings.Amount of Analyst CoveragePTC Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.31% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in PTC Therapeutics has recently decreased by 0.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.38. Previous Next 2.7 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for PTC Therapeutics this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 2 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $165,506.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($5.94) to ($5.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About PTC Therapeutics Stock (NASDAQ:PTCT)PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More PTCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTCT Stock News HeadlinesApril 23, 2024 | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 3,361 Shares of StockApril 20, 2024 | insidertrades.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells 787 Shares of StockApril 25, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 5, 2024 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $14,922.62 in StockApril 25, 2024 | prnewswire.comPTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsApril 23, 2024 | prnewswire.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 23, 2024 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Reduce" from BrokeragesApril 21, 2024 | americanbankingnews.comEric Pauwels Sells 787 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockApril 25, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 21, 2024 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down to $24.69April 21, 2024 | investing.comPTC Therapeutics CEO sells shares worth over $19kApril 18, 2024 | americanbankingnews.comPTC Therapeutics (PTCT) Set to Announce Quarterly Earnings on ThursdayApril 11, 2024 | finance.yahoo.comPTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsApril 11, 2024 | prnewswire.comPTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsApril 1, 2024 | msn.comSolid Biosciences gets FDA rare pediatric disease status for DMD therapyMarch 28, 2024 | finance.yahoo.comPTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMAMarch 19, 2024 | markets.businessinsider.comBuy Rating for PTC Therapeutics Bolstered by Positive Regulatory Prospects and Gene Therapy AdvancesMarch 19, 2024 | markets.businessinsider.comPTC Therapeutics Gains After Announcement Of Key Regulatory UpdatesMarch 19, 2024 | finanznachrichten.dePTC Therapeutics, Inc.: PTC Therapeutics Provides Key Regulatory UpdatesMarch 19, 2024 | markets.businessinsider.comPTC Therapeutics Submits BLA To FDA For Upstaza - Quick FactsMarch 19, 2024 | finance.yahoo.comPTC Therapeutics Provides Key Regulatory UpdatesMarch 7, 2024 | markets.businessinsider.comPTC Therapeutics: Navigating Challenges and Pursuing Growth Amidst Regulatory HurdlesMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for PTC Therapeutics Amid Promising Regulatory Progress and Market OpportunityMarch 2, 2024 | finance.yahoo.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comPTC Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 1, 2024 | markets.businessinsider.comPTC Therapeutics: Hold Rating Amidst Revenue Downturn and Regulatory HurdlesFebruary 29, 2024 | finance.yahoo.comPTC Therapeutics Inc (PTCT) Reports Robust Revenue Growth and Advances in PipelineSee More Headlines Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Confirmed)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees988Year FoundedN/APrice Target and Rating Average Stock Price Target$33.53 High Stock Price Target$55.00 Low Stock Price Target$17.00 Potential Upside/Downside+31.8%Consensus RatingReduce Rating Score (0-4)1.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($8.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-626,600,000.00 Net Margins-66.82% Pretax Margin-74.23% Return on EquityN/A Return on Assets-32.06% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio1.97 Sales & Book Value Annual Sales$937.82 million Price / Sales2.08 Cash Flow$2.43 per share Price / Cash Flow10.49 Book Value($10.85) per share Price / Book-2.34Miscellaneous Outstanding Shares76,610,000Free Float72,548,000Market Cap$1.95 billion OptionableOptionable Beta0.67 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Matthew B. Klein F.A.C.S. (Age 52)M.D., M.S., CEO & Director Comp: $995.4kDr. Stuart W. Peltz Ph.D. (Age 64)Co-Founder, Senior Consultant & Member of Scientific Advisory Board Comp: $1.54MDr. Allan Steven Jacobson Ph.D. (Age 78)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $145kDr. Neil Almstead Ph.D. (Age 57)Chief Technical Operations Officer Comp: $829.97kMr. Eric Pauwels (Age 63)Chief Business Officer Comp: $847.67kMr. Pierre Gravier M.S. (Age 38)Chief Financial Officer Ms. Christine Utter (Age 46)Senior VP, Chief Accounting Officer & Head of People Services Comp: $595.54kAlex KaneInvestor Relations OfficerMr. Mark Elliott Boulding (Age 63)Executive VP & Chief Legal Officer Comp: $824.09kMs. Jane BajVice President of Corporate CommunicationsMore ExecutivesKey CompetitorsMaravai LifeSciencesNASDAQ:MRVIGalapagosNASDAQ:GLPGNewAmsterdam PharmaNASDAQ:NAMSGeronNASDAQ:GERNKeros TherapeuticsNASDAQ:KROSView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 63,570 shares on 4/24/2024Ownership: 0.400%Matthew B KleinSold 3,361 sharesTotal: $83,655.29 ($24.89/share)Allspring Global Investments Holdings LLCBought 1,574 shares on 4/18/2024Ownership: 0.002%Eric PauwelsSold 787 sharesTotal: $19,785.18 ($25.14/share)Los Angeles Capital Management LLCBought 2,024 shares on 4/5/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions PTCT Stock Analysis - Frequently Asked Questions Should I buy or sell PTC Therapeutics stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 5 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" PTCT shares. View PTCT analyst ratings or view top-rated stocks. What is PTC Therapeutics' stock price target for 2024? 13 Wall Street analysts have issued 12 month price objectives for PTC Therapeutics' shares. Their PTCT share price targets range from $17.00 to $55.00. On average, they predict the company's share price to reach $33.53 in the next year. This suggests a possible upside of 31.6% from the stock's current price. View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts. How have PTCT shares performed in 2024? PTC Therapeutics' stock was trading at $27.56 on January 1st, 2024. Since then, PTCT stock has decreased by 7.5% and is now trading at $25.49. View the best growth stocks for 2024 here. When is PTC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our PTCT earnings forecast. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings data on Thursday, February, 29th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by $0.53. The biopharmaceutical company had revenue of $307.06 million for the quarter, compared to analysts' expectations of $315.90 million. What ETFs hold PTC Therapeutics' stock? ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), SPDR S&P Biotech ETF (XBI) and Harbor Corporate Culture Small Cap ETF (HAPS). What guidance has PTC Therapeutics issued on next quarter's earnings? PTC Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $606.6 million. What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD). Who are PTC Therapeutics' major shareholders? PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.40%), Los Angeles Capital Management LLC (0.01%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTCT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
